NEW YORK (GenomeWeb News) – OncoMethylome Sciences said Tuesday it has contracted the German company Signature Diagnostics to help it manage the German component of its multi-center clinical trials for a colorectal cancer diagnostic.
 
Under the agreement, OncoMethylome also has acquired a minority interest in Potsdam-based Signature Diagnostics, and it will give the company an up-front payment as well as service fees. Additional financial terms of the agreement were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.